Gene Solutions Vietnam and Ho Chi Minh City Oncology Hospital Join Forces to Expand the Application of Advanced Genomic Technologies in Cancer Care

  • News

Progress in precision oncology does not happen through innovation alone. It is built on scientific evidence, clinical collaboration, and a shared commitment to improving patient outcomes.

 Gene Solutions Vietnam and Ho Chi Minh City Oncology Hospital Advanced Genomic Technologies in Cancer Care MCED SPOTMAS 10 US.FDA Breakthrough Device Designation

With this vision in mind, on 27 July, Gene Solutions Vietnam and Ho Chi Minh City Oncology Hospital signed a Memorandum of Understanding (MOU) to strengthen collaboration in advancing genomic technologies for cancer care in Vietnam.
Gene Solutions Vietnam and Ho Chi Minh City Oncology Hospital Advanced Genomic Technologies in Cancer Care MCED SPOTMAS 10 US.FDA Breakthrough Device Designation
Speaking at the signing ceremony, Dr. Nguyen Huu Nguyen, Co-founder and Deputy Chief Executive Officer of Gene Solutions, said:
“Through this partnership, Gene Solutions aims to further advance precision medicine in clinical practice while building an integrated ecosystem that connects clinical and genomic data, bringing innovative technologies closer to physicians, patients, and healthcare systems.”
Gene Solutions Vietnam and Ho Chi Minh City Oncology Hospital Advanced Genomic Technologies in Cancer Care MCED SPOTMAS 10 US.FDA Breakthrough Device Designation
Echoing this shared commitment, Dr. Diep Bao Tuan, Director of Ho Chi Minh City Oncology Hospital, highlighted the hospital’s vision of strengthening early cancer detection through integrated screening approaches before specialized diagnostic investigations. He also noted the potential of SPOT-MAS 10, which has received U.S. FDA Breakthrough Device Designation*, to expand access to efficient and evidence-based multi-cancer screening in the future.
Gene Solutions Vietnam and Ho Chi Minh City Oncology Hospital Advanced Genomic Technologies in Cancer Care MCED SPOTMAS 10 US.FDA Breakthrough Device Designation

We sincerely thank Ho Chi Minh City Oncology Hospital for its trust and partnership. Together, we look forward to bringing high-quality genomic technologies to more patients across Vietnam and generating robust evidence from local populations, strengthening the foundation for broader adoption of precision medicine across Asia.

Gene Solutions Vietnam and Ho Chi Minh City Oncology Hospital Advanced Genomic Technologies in Cancer Care MCED SPOTMAS 10 US.FDA Breakthrough Device Designation

Learn more about our solutions: https://genesolutions.com/our-solutions

Learn more about SPOT-MAS 10: https://genesolutions.com/our-test/spot-mas

*Breakthrough Device Designation is not FDA approval, clearance, or marketing authorization. SPOT-MAS 10 remains subject to future FDA review.

Facebook
Twitter
Pinterest

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More